Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
OTC Drugs

P&G, Colgate Savor Strengthening Of Brands Against Private Label

This article was originally published in The Tan Sheet

  • News

Executive Summary

Procter & Gamble and Colgate-Palmolive, after noting concerns about losing market share to private label since the onset of the economic recession, are touting the growing strength of their branded products over generics.

You may also be interested in...



P&G Sues Vi-Jon Over Scope Outlast Lookalike Trade Dress

Procter & Gamble fights back against a private labeler making mouthwash packaging that P&G says infringes on trade dress patents for Scope Outlast.

P&G Sues Vi-Jon Over Scope Outlast Lookalike Trade Dress

Procter & Gamble fights back against a private labeler making mouthwash packaging that P&G says infringes on trade dress patents for Scope Outlast.

P&G, Colgate Hike Prices To Offset Rising Commodity Costs

Procter & Gamble and Colgate-Palmolive are among a number of major consumer products companies initiating price increases in order to offset rising commodity costs

Table

View full table

Topics

Tags:
OTC Drugs
Latest Headlines

Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings

China’s Public Payer Wants To Define Innovative Drugs As Those With ‘Novel Benefits’

Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116

Woodcock Takes On Rare Disease Challenges In Retirement, Keeps FDA, Industry At Arm’s Length

See All
UsernamePublicRestriction

Register

PS105071

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By